{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:57:54Z","timestamp":1792699074117,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017 SGR 263"],"award-info":[{"award-number":["2017 SGR 263"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["SLT008\/18\/00061"],"award-info":[{"award-number":["SLT008\/18\/00061"]}],"id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00406-022-01439-z","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T22:02:36Z","timestamp":1655416956000},"page":"243-252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Cost-effectiveness of Alzheimer\u2019s disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis"],"prefix":"10.1007","volume":"273","author":[{"given":"Jose","family":"Contador","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Magdalena","family":"Vargas-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"S\u00e1nchez-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Trapero-Bertran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Llad\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"1439_CR1","unstructured":"World Health Organization (2021) Global status report on the public health response to dementia. World Health Organization. https:\/\/apps.who.int\/iris\/handle\/10665\/344701. Accessed 15 Jan 2022"},{"key":"1439_CR2","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","volume":"80","author":"CR Jack","year":"2013","unstructured":"Jack CR, Holtzman DM (2013) Biomarker modeling of Alzheimer\u2019s disease. Neuron 80:1347\u20131358. https:\/\/doi.org\/10.1016\/j.neuron.2013.12.003","journal-title":"Neuron"},{"key":"1439_CR3","first-page":"38","volume":"3","author":"XC Zhu","year":"2015","unstructured":"Zhu XC, Tan L, Wang HF et al (2015) Rate of early onset Alzheimer\u2019s disease: a systematic review and meta-analysis. Ann Transl Med 3:38","journal-title":"Ann Transl Med"},{"key":"1439_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1177\/1533317512454711","volume":"27","author":"MF Mendez","year":"2012","unstructured":"Mendez MF, Lee AS, Joshi A, Shapira JS (2012) Nonamnestic presentations of early-onset Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen 27:413\u2013420. https:\/\/doi.org\/10.1177\/1533317512454711","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"1439_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement 7:263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimer\u2019s Dement"},{"key":"1439_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement 7:270\u2013279. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008","journal-title":"Alzheimer\u2019s Dement"},{"key":"1439_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement 14:535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimer\u2019s Dement"},{"key":"1439_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jalz.2009.01.028","volume":"5","author":"DL Weimer","year":"2009","unstructured":"Weimer DL, Sager MA (2009) Early identification and treatment of Alzheimer\u2019s disease: social and fiscal outcomes. Alzheimer\u2019s Dement 5:215\u2013226. https:\/\/doi.org\/10.1016\/j.jalz.2009.01.028","journal-title":"Alzheimer\u2019s Dement"},{"key":"1439_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F et al (2017) Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol 16:661\u2013676. https:\/\/doi.org\/10.1016\/S1474-4422(17)30159-X","journal-title":"Lancet Neurol"},{"key":"1439_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12962-021-00300-9","volume":"19","author":"YS Lee","year":"2021","unstructured":"Lee YS, Youn HC, Jeong HG et al (2021) Cost-effectiveness of using amyloid positron emission tomography in individuals with mild cognitive impairment. Cost Eff Resour Alloc 19:1\u201310. https:\/\/doi.org\/10.1186\/s12962-021-00300-9","journal-title":"Cost Eff Resour Alloc"},{"key":"1439_CR11","first-page":"63","volume":"18","author":"J Hornberger","year":"2015","unstructured":"Hornberger J, Michalopoulos S, Dai M et al (2015) Cost-Effectiveness of florbetapir-PET in Alzheimer\u2019s disease: a Spanish societal perspective. J Ment Health Policy Econ 18:63\u201373","journal-title":"J Ment Health Policy Econ"},{"key":"1439_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/548157","volume":"2012","author":"S Guo","year":"2012","unstructured":"Guo S, Getsios D, Hernandez L et al (2012) Florbetaben PET in the early diagnosis of Alzheimer\u2019s disease: a discrete event simulation to explore its potential value and key data gaps. Int J Alzheimer\u2019s Dis 2012:1\u201317. https:\/\/doi.org\/10.1155\/2012\/548157","journal-title":"Int J Alzheimer's Dis"},{"key":"1439_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-017-0243-0","volume":"9","author":"SAW Lee","year":"2017","unstructured":"Lee SAW, Sposato LA, Hachinski V, Cipriano LE (2017) Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 9:1\u201314. https:\/\/doi.org\/10.1186\/s13195-017-0243-0","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"1439_CR14","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3233\/JAD-170324","volume":"60","author":"RLH Handels","year":"2017","unstructured":"Handels RLH, Wimo A, Dodel R et al (2017) Cost-utility of using Alzheimer\u2019s disease biomarkers in cerebrospinal fluid to predict progression from mild cognitive impairment to dementia. J Alzheimer\u2019s Dis 60:1477\u20131487. https:\/\/doi.org\/10.3233\/JAD-170324","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1439_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3233\/JAD-132216","volume":"42","author":"C Valc\u00e1rcel-Nazco","year":"2014","unstructured":"Valc\u00e1rcel-Nazco C, Perestelo-P\u00e9rez L, Molinuevo JL et al (2014) Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 42:777\u2013788. https:\/\/doi.org\/10.3233\/JAD-132216","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1439_CR16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.trci.2019.06.001","volume":"5","author":"R Wittenberg","year":"2019","unstructured":"Wittenberg R, Knapp M, Karagiannidou M et al (2019) Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer\u2019s disease patients. Alzheimer\u2019s Dement Transl Res Clin Interv 5:382\u2013387. https:\/\/doi.org\/10.1016\/j.trci.2019.06.001","journal-title":"Alzheimer\u2019s Dement Transl Res Clin Interv"},{"key":"1439_CR17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/1471-0528.17012","volume":"129","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F et al (2022) Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BJOG 129:336\u2013344. https:\/\/doi.org\/10.1111\/1471-0528.17012","journal-title":"BJOG"},{"key":"1439_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10030158","author":"T Rautenberg","year":"2020","unstructured":"Rautenberg T, Gerritsen A, Downes M (2020) Health economic decision tree models of diagnostics for dummies: a pictorial primer. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics10030158","journal-title":"Diagnostics"},{"key":"1439_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka SK et al (2009) Cerebrospinal fluid \u03b2-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66:382\u2013389. https:\/\/doi.org\/10.1001\/archneurol.2008.596","journal-title":"Arch Neurol"},{"key":"1439_CR20","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1002\/hbm.24782","volume":"40","author":"A Chandra","year":"2019","unstructured":"Chandra A, Valkimadi PE, Pagano G et al (2019) Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer\u2019s disease and mild cognitive impairment. Hum Brain Mapp 40:5424\u20135442. https:\/\/doi.org\/10.1002\/hbm.24782","journal-title":"Hum Brain Mapp"},{"key":"1439_CR21","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, United Kingdom"},{"issue":"1","key":"1439_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/alz.12372","volume":"18","author":"H Hampel","year":"2021","unstructured":"Hampel H, Lle\u00f3 A, Ikeuchi T et al (2021) State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer \u2019 s disease. Alzheimer\u2019s Dementia 18(1):159\u2013177. https:\/\/doi.org\/10.1002\/alz.12372","journal-title":"Alzheimer's Dementia"},{"key":"1439_CR23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/ene.13945","volume":"26","author":"N Falg\u00e0s","year":"2019","unstructured":"Falg\u00e0s N, Tort-Merino A, Balasa M et al (2019) Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment. Eur J Neurol 26:1098\u20131104. https:\/\/doi.org\/10.1111\/ene.13945","journal-title":"Eur J Neurol"},{"key":"1439_CR24","doi-asserted-by":"publisher","first-page":"CD009132","DOI":"10.1002\/14651858.CD009132.pub2","volume":"2012","author":"TC Russ","year":"2012","unstructured":"Russ TC, Morling JR (2012) Cholinesterase inhibitors for mild cognitive impairment. Cochrane database Syst Rev 2012:CD009132. https:\/\/doi.org\/10.1002\/14651858.CD009132.pub2","journal-title":"Cochrane database Syst Rev"},{"key":"1439_CR25","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaneurol.2016.3751","volume":"73","author":"M Boccardi","year":"2016","unstructured":"Boccardi M, Altomare D, Ferrari C et al (2016) Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET with [18F]-florbetapir (INDIA-FBP) study. JAMA Neurol 73:1417\u20131424. https:\/\/doi.org\/10.1001\/jamaneurol.2016.3751","journal-title":"JAMA Neurol"},{"key":"1439_CR26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/03007995.2016.1277197","volume":"33","author":"J Hornberger","year":"2017","unstructured":"Hornberger J, Bae J, Watson I et al (2017) Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer\u2019s disease\u2014the case of florbetapir. Curr Med Res Opin 33:675\u2013685. https:\/\/doi.org\/10.1080\/03007995.2016.1277197","journal-title":"Curr Med Res Opin"},{"key":"1439_CR27","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.neurobiolaging.2008.02.007","volume":"30","author":"FH Bouwman","year":"2009","unstructured":"Bouwman FH, Schoonenboom NSM, Verwey NA et al (2009) CSF biomarker levels in early and late onset Alzheimer\u2019s disease. Neurobiol Aging 30:1895\u20131901. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2008.02.007","journal-title":"Neurobiol Aging"},{"key":"1439_CR28","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Pegueroles J, Mu\u00f1oz L et al (2019) Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse. Ann Clin Transl Neurol 6:1815\u20131824. https:\/\/doi.org\/10.1002\/acn3.50873","journal-title":"Ann Clin Transl Neurol"},{"key":"1439_CR29","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/acn3.50897","volume":"6","author":"M Bongianni","year":"2019","unstructured":"Bongianni M, Ladogana A, Capaldi S et al (2019) \u03b1-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Ann Clin Transl Neurol 6:2120\u20132126. https:\/\/doi.org\/10.1002\/acn3.50897","journal-title":"Ann Clin Transl Neurol"},{"key":"1439_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi M, Candelise N, Baiardi S et al (2020) Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140:49\u201362. https:\/\/doi.org\/10.1007\/s00401-020-02160-8","journal-title":"Acta Neuropathol"},{"key":"1439_CR31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB et al (2021) Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol 20:484\u2013496. https:\/\/doi.org\/10.1016\/S1474-4422(21)00066-1","journal-title":"Lancet Neurol"},{"key":"1439_CR32","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1007\/s00259-020-05156-4","volume":"48","author":"GN Bischof","year":"2021","unstructured":"Bischof GN, Dodich A, Boccardi M et al (2021) Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging 48:2110\u20132120. https:\/\/doi.org\/10.1007\/s00259-020-05156-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1439_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/0272989X09347013","volume":"29","author":"PMM Bossuyt","year":"2009","unstructured":"Bossuyt PMM, McCaffery K (2009) Additional patient outcomes and pathways in evaluations of testing. Med Decis Mak 29:30\u201338. https:\/\/doi.org\/10.1177\/0272989X09347013","journal-title":"Med Decis Mak"},{"key":"1439_CR34","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2021.2161","volume":"78","author":"S Hendriks","year":"2021","unstructured":"Hendriks S, Peetoom K, Bakker C et al (2021) Global Prevalence of Young-Onset Dementia. JAMA Neurol 78:1080. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2161","journal-title":"JAMA Neurol"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-022-01439-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-022-01439-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-022-01439-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T08:55:53Z","timestamp":1700729753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-022-01439-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1007\/s00406-022-01439-z","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}